These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 20843836)

  • 21. A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors.
    Montero AJ; Kwon D; Flores A; Kovacs K; Trent JC; Benedetto P; Rocha-Lima C; Merchan JR
    Clin Cancer Res; 2016 Jul; 22(13):3209-17. PubMed ID: 26864210
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Co-occurring adverse events enable early prediction of progression-free survival in metastatic renal cell carcinoma patients treated with sunitinib: a hypothesis-generating study.
    Kucharz J; Dumnicka P; Kuzniewski M; Kusnierz-Cabala B; Herman RM; Krzemieniecki K
    Tumori; 2015; 101(5):555-9. PubMed ID: 26045121
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sunitinib-induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma.
    Rautiola J; Donskov F; Peltola K; Joensuu H; Bono P
    BJU Int; 2016 Jan; 117(1):110-7. PubMed ID: 25252180
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure.
    Deprimo SE; Huang X; Blackstein ME; Garrett CR; Harmon CS; Schöffski P; Shah MH; Verweij J; Baum CM; Demetri GD
    Clin Cancer Res; 2009 Sep; 15(18):5869-77. PubMed ID: 19737953
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Exploratory analysis of the effect of toxicity of sunitinib on the clinical outcome of patients with advanced renal cell carcinoma].
    Hong YP; Yao XD; Zhu Y; Ye DW; Shi GH; Zhang SL; Dai B; Zhang HL; Shen YJ; Zhu YP; Ma CG; Xiao WJ; Qin XJ; Lin GW
    Zhonghua Yi Xue Za Zhi; 2013 Sep; 93(36):2880-3. PubMed ID: 24373400
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study.
    Garcia-Donas J; Esteban E; Leandro-García LJ; Castellano DE; González del Alba A; Climent MA; Arranz JA; Gallardo E; Puente J; Bellmunt J; Mellado B; Martínez E; Moreno F; Font A; Robledo M; Rodríguez-Antona C
    Lancet Oncol; 2011 Nov; 12(12):1143-50. PubMed ID: 22015057
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synergistic Survival: A New Phenomenon Connected to Adverse Events of First-Line Sunitinib Treatment in Advanced Renal Cell Carcinoma.
    Nagyiványi K; Budai B; Bíró K; Gyergyay F; Noszek L; Küronya Z; Németh H; Nagy P; Géczi L
    Clin Genitourin Cancer; 2016 Aug; 14(4):314-22. PubMed ID: 26774206
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exposure-response relationships in patients with metastatic renal cell carcinoma receiving sunitinib: maintaining optimum efficacy in clinical practice.
    Ravaud A; Bello CL
    Anticancer Drugs; 2011 Jun; 22(5):377-83. PubMed ID: 21394020
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dosing patterns, toxicity, and outcomes in patients treated with first-line sunitinib for advanced renal cell carcinoma in community-based practices.
    Schnadig ID; Hutson TE; Chung H; Dhanda R; Halm M; Forsyth M; Vogelzang NJ
    Clin Genitourin Cancer; 2014 Dec; 12(6):413-21. PubMed ID: 25163396
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic-pharmacodynamic analysis of sunitinib-induced thrombocytopenia in Japanese patients with renal cell carcinoma.
    Nagata M; Ishiwata Y; Takahashi Y; Takahashi H; Saito K; Fujii Y; Kihara K; Yasuhara M
    Biol Pharm Bull; 2015; 38(3):402-10. PubMed ID: 25757921
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma.
    Diekstra MH; Swen JJ; Boven E; Castellano D; Gelderblom H; Mathijssen RH; Rodríguez-Antona C; García-Donas J; Rini BI; Guchelaar HJ
    Eur Urol; 2015 Oct; 68(4):621-9. PubMed ID: 25930089
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.
    Houk BE; Bello CL; Poland B; Rosen LS; Demetri GD; Motzer RJ
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):357-71. PubMed ID: 19967539
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children's Oncology Group study.
    DuBois SG; Shusterman S; Reid JM; Ingle AM; Ahern CH; Baruchel S; Glade-Bender J; Ivy P; Adamson PC; Blaney SM
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):1021-7. PubMed ID: 22179104
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial.
    Cheng AL; Kang YK; Lin DY; Park JW; Kudo M; Qin S; Chung HC; Song X; Xu J; Poggi G; Omata M; Pitman Lowenthal S; Lanzalone S; Yang L; Lechuga MJ; Raymond E
    J Clin Oncol; 2013 Nov; 31(32):4067-75. PubMed ID: 24081937
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib.
    Faivre S; Zappa M; Vilgrain V; Boucher E; Douillard JY; Lim HY; Kim JS; Im SA; Kang YK; Bouattour M; Dokmak S; Dreyer C; Sablin MP; Serrate C; Cheng AL; Lanzalone S; Lin X; Lechuga MJ; Raymond E
    Clin Cancer Res; 2011 Jul; 17(13):4504-12. PubMed ID: 21531821
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy, Safety, and Potential Biomarkers of Sunitinib and Transarterial Chemoembolization (TACE) Combination in Advanced Hepatocellular Carcinoma (HCC): Phase II Trial.
    Pokuri VK; Tomaszewski GM; Ait-Oudhia S; Groman A; Khushalani NI; Lugade AA; Thanavala Y; Ashton EA; Grande C; Fetterly GJ; Iyer R
    Am J Clin Oncol; 2018 Apr; 41(4):332-338. PubMed ID: 27014931
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.
    Park SJ; Lee JL; Park I; Park K; Ahn Y; Ahn JH; Lee DH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
    Chemotherapy; 2012; 58(6):468-74. PubMed ID: 23548259
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06).
    Koeberle D; Montemurro M; Samaras P; Majno P; Simcock M; Limacher A; Lerch S; Kovàcs K; Inauen R; Hess V; Saletti P; Borner M; Roth A; Bodoky G
    Oncologist; 2010; 15(3):285-92. PubMed ID: 20203173
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug monitoring of sunitinib in patients with advanced solid tumors: a monocentric observational French study.
    Cabel L; Blanchet B; Thomas-Schoemann A; Huillard O; Bellesoeur A; Cessot A; Giroux J; Boudou-Rouquette P; Coriat R; Vidal M; Saidu NEB; Golmard L; Alexandre J; Goldwasser F
    Fundam Clin Pharmacol; 2018 Feb; 32(1):98-107. PubMed ID: 29055166
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial.
    Kroiss M; Quinkler M; Johanssen S; van Erp NP; Lankheet N; Pöllinger A; Laubner K; Strasburger CJ; Hahner S; Müller HH; Allolio B; Fassnacht M
    J Clin Endocrinol Metab; 2012 Oct; 97(10):3495-503. PubMed ID: 22837187
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.